- CEO to participate in panel discussion, fireside chat focusing on psychedelics
- The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape
- CYBN is implementing a three-pillar strategy
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin CEO’s upcoming participation in two virtual investor conferences (https://ibn.fm/1zAF4).
The company announced that CEO Doug Drysdale has been invited to participate in a panel discussion titled “Psychedelics: More Than Just a Trip” during the 11th annual LifeSci Partners Corporate Access Event. The two-day event is slated for Jan. 5–7, 2022, with the panel discussion scheduled for Wednesday, Jan. 5, at 10 a.m. EST. (Click here to register and access the webcast.)
In addition, Drysdale will participate in a fireside chat during the virtual three-day H.C. Wainwright Bioconnect Conference. Drysdale’s fireside chat will be available on demand beginning Jan. 10, 2022, at 7 a.m. EST. (Click here to register and access the webcast.)
Drysdale’s expertise in the psychedelics field is being recognized as Cybin continues to establish itself as a leading ethical biopharmaceutical company. The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape. To accomplish this lofty vision, Cybin is following a three-pillar strategy based on the following: novel drug-discovery platform (API modification), proprietary drug-delivery systems (R&D) and innovative treatment regimens (https://ibn.fm/vMkCy).
Cybin is developing new APIs through selective modifications of tryptamine and phenethylamine-based scaffolds specifically to alter their pharmacokinetics without modifying their therapeutic potential. These modifications involve replacing selective hydrogens with deuterium atoms.
The company’s R&D, categorized under the proprietary drug-delivery systems, involves the development of an efficient delivery system that attempts to bypass liver metabolism with a direct path to the brain, thereby providing faster onset. The company is also looking to identify modified-release formulations with the potential to reduce side effects and control exposure, as well as providing dose control through its proprietary device platform.
Cybin’s treatment regimen is where science meets technology. Its exclusive EMBARK is a best-practices psychotherapy program designed to provide consistent therapist training and consistent psychotherapy delivery in clinical trials.
Cybin is a leading ethical biopharmaceutical company and is working with a network of world-class partners and internationally recognized scientists to create safe and effective therapeutics for patients to address a multitude of mental health issues. The company operates in the United States, the United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork